Steven Seedhouse
Stock Analyst at Cantor Fitzgerald
(3.11)
# 1,170
Out of 5,123 analysts
172
Total ratings
45.1%
Success rate
0.8%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $6.42 | +304.98% | 2 | Oct 15, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $48.13 | +30.90% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $12.26 | +1,099.02% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $103.96 | -21.12% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $13.33 | -24.98% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $26.62 | +5.20% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $0.84 | +1,090.48% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $29.56 | +251.83% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $4.02 | +447.26% | 2 | Dec 11, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $1.55 | +803.23% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $146.23 | -36.40% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $42.74 | +59.10% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $23.15 | +357.88% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $7.38 | +103.25% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $18.23 | +207.19% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $12.36 | +361.17% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $6.01 | +266.06% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $1.95 | +771.79% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.33 | +951.05% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $77.63 | -51.05% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $72.72 | -2.37% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $2.46 | +103.25% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $48.38 | -21.46% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $7.33 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.30 | - | 14 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.64 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $9.71 | +2,680.64% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $185.45 | - | 2 | Apr 23, 2020 |
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $6.42
Upside: +304.98%
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $48.13
Upside: +30.90%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $12.26
Upside: +1,099.02%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $103.96
Upside: -21.12%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $13.33
Upside: -24.98%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $26.62
Upside: +5.20%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $0.84
Upside: +1,090.48%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $29.56
Upside: +251.83%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $4.02
Upside: +447.26%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.55
Upside: +803.23%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $146.23
Upside: -36.40%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $42.74
Upside: +59.10%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $23.15
Upside: +357.88%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $7.38
Upside: +103.25%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $18.23
Upside: +207.19%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $12.36
Upside: +361.17%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $6.01
Upside: +266.06%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $1.95
Upside: +771.79%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.33
Upside: +951.05%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $77.63
Upside: -51.05%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $72.72
Upside: -2.37%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $2.46
Upside: +103.25%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $48.38
Upside: -21.46%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $7.33
Upside: -
Aug 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.30
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.64
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $9.71
Upside: +2,680.64%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $185.45
Upside: -